Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial completed LPLV in early 2026 per sponsor updates; full results expected 1H CY26 but no public readout found as of Apr 2026. No sources frame outcomes as positive or negative; evidence incomplete.
Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial (NCT05466799/TRIPP-FFX) is Phase 2, active not recruiting with primary completion Jan 2026. LPLV completed ~Jan 2026; data cleaning ongoing. No public efficacy readout, results, or framing (positive/negative) for LDCR/safety of this exact randomized trial vs FOLFIRINOX alone. Prior OncoSil studies (different chemo/regimens) reported positive signals but are not this trial.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:20 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed91% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout was found. Sponsor materials show TRIPP-FFX completed recruitment in July 2025 with data expected in early 2026, and as of January 28, 2026 the study had only reached last-patient-last-visit and was still in data cleaning/statistical analysis for a future 1H 2026 presentation.
Found Apr 1, 2026, 6:39 PMReviewed Apr 1, 2026, 6:46 PM
Sponsoroncosil.comJul 25, 2025, 12:00 AM
Completion of Recruitment in TRIPP-FFX Clinical Trial
Sponsor said recruitment was complete and expected TRIPP-FFX data to become available in early calendar 2026, indicating no readout yet at that point.
Sponsorannouncements.asx.com.auJan 28, 2026, 12:00 AM
ASX Announcement: TRIPP-FFX Clinical Trial Completes Last Patient, Last Visit
On January 28, 2026, OncoSil said LPLV had been achieved and the trial would now move to final data cleaning, database lock, statistical analysis, with results planned for presentation in 1H 2026.